收费全文 | 246093篇 |
免费 | 17830篇 |
国内免费 | 1091篇 |
耳鼻咽喉 | 2769篇 |
儿科学 | 6439篇 |
妇产科学 | 4578篇 |
基础医学 | 32110篇 |
口腔科学 | 4516篇 |
临床医学 | 24744篇 |
内科学 | 51521篇 |
皮肤病学 | 3370篇 |
神经病学 | 23748篇 |
特种医学 | 8321篇 |
外国民族医学 | 11篇 |
外科学 | 38110篇 |
综合类 | 3412篇 |
一般理论 | 318篇 |
预防医学 | 20782篇 |
眼科学 | 6485篇 |
药学 | 16795篇 |
4篇 | |
中国医学 | 357篇 |
肿瘤学 | 16624篇 |
2023年 | 1204篇 |
2022年 | 919篇 |
2021年 | 4192篇 |
2020年 | 3214篇 |
2019年 | 5236篇 |
2018年 | 5904篇 |
2017年 | 4466篇 |
2016年 | 4886篇 |
2015年 | 5767篇 |
2014年 | 8562篇 |
2013年 | 11739篇 |
2012年 | 17985篇 |
2011年 | 18870篇 |
2010年 | 10524篇 |
2009年 | 9377篇 |
2008年 | 16567篇 |
2007年 | 17418篇 |
2006年 | 17278篇 |
2005年 | 17245篇 |
2004年 | 16162篇 |
2003年 | 15019篇 |
2002年 | 14019篇 |
2001年 | 2066篇 |
2000年 | 1544篇 |
1999年 | 2132篇 |
1998年 | 2569篇 |
1997年 | 2083篇 |
1996年 | 1775篇 |
1995年 | 2041篇 |
1994年 | 1700篇 |
1993年 | 1525篇 |
1992年 | 1223篇 |
1991年 | 1144篇 |
1990年 | 983篇 |
1989年 | 960篇 |
1988年 | 942篇 |
1987年 | 927篇 |
1986年 | 930篇 |
1985年 | 955篇 |
1984年 | 1190篇 |
1983年 | 1100篇 |
1982年 | 1317篇 |
1981年 | 1283篇 |
1980年 | 1122篇 |
1979年 | 689篇 |
1978年 | 732篇 |
1977年 | 619篇 |
1976年 | 564篇 |
1975年 | 455篇 |
1974年 | 467篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献